Using T2-Exchange from Ln3+DOTA-Based Chelates for Contrast-Enhanced Molecular Imaging of Prostate Cancer with MRI
Technical Report,01 Feb 2014,31 Jan 2016
University of Texas, Southwestern Medical Center at Dallas Dallas United States
Pagination or Media Count:
Purpose To develop a targeted T2-exchange MRI contrast agent for the early detection and diagnosis of prostate cancer. Scope This contrast agent is based on T2 contrast i.e., hypo-intense contrast arising from water molecule exchange between the inner-sphere of a Dysprosium Dy3 central ion and the bulk water. The level of this T2-exchange contrast is highly dependent on both the water molecule exchange rate and the paramagnetic shift of the water molecule hydrogen protons when bound to the Dy3 ion. After identifying which DyDOTA-based chelate gave the optimal water molecule exchange rate at 9.4 T MRI, the chelate would then be polymerized to increase the transverse relaxivity r2 per molecule by 100 fold. Thereby creating a highly sensitive, low molecular weight T2 contrast agent for cancer molecular imaging with MRI. Polymers targeting the prostate specific membrane antigen PSMA of prostate cancer cells would then be synthesized and tested with both in vitro and in vivo experiments.
- Medicine and Medical Research